公开(公告)号：US20250144273A1

公开(公告)日：2025-05-08

申请号：US19014053

申请日：2025-01-08

Applicant: SAGA UNIVERSITY ,  KYOCERA CORPORATION

Inventor： Masaaki MAWATARI ,  Masatsugu TSUKAMOTO ,  Iwao NODA

IPC: A61L27/54 ,  A61L27/32

Abstract: Provided is a bioimplant which is capable to inhibit the biofilm formation over a long period of time after an operation. The bioimplant of the present invention comprises a base material of metal, ceramic, or plastic and a thermal spraying film of a calcium phosphate-based material formed at least partially thereon and the silver concentration in the thermal-spray film is 0.05 wt % to 3.00 wt %.

公开(公告)号：US12226550B2

公开(公告)日：2025-02-18

申请号：US18086506

申请日：2022-12-21

Applicant: SAGA UNIVERSITY ,  KYOCERA CORPORATION

Inventor： Masaaki Mawatari ,  Masatsugu Tsukamoto ,  Iwao Noda

IPC: A61L27/32 ,  A61L27/54

Abstract: Provided is a bioimplant which is capable to inhibit the biofilm formation over a long period of time after an operation. The bioimplant of the present invention comprises a base material of metal, ceramic, or plastic and a thermal spraying film of a calcium phosphate-based material formed at least partially thereon and the silver concentration in the thermal-spray film is 0.05 wt % to 3.00 wt %.

公开(公告)号：US12162854B2

公开(公告)日：2024-12-10

申请号：US17054397

申请日：2019-05-10

Applicant: DAIKIN INDUSTRIES, LTD. ,  SAGA UNIVERSITY

Inventor： Masahiro Higashi ,  Yosuke Kishikawa ,  Tsugio Kitamura

IPC: C07C49/233 ,  C07C45/67 ,  C07C201/12 ,  C07C231/12 ,  C07D333/22 ,  C07C49/813 ,  C07C205/45 ,  C07C233/33

Abstract: A method for producing a fluoromethyl derivative represented by formula (1), the method including step A of reacting an alkene compound represented by formula (2) with a fluorine source represented by formula MFn, in the presence of a hypervalent-iodine aromatic compound (1a), or in the presence of an aromatic iodine compound (1b) and an oxidant (A) to fluorinate the alkene compound.

公开(公告)号：US12091382B2

公开(公告)日：2024-09-17

申请号：US17522312

申请日：2021-11-09

Applicant: DAIKIN INDUSTRIES, LTD. ,  SAGA UNIVERSITY

Inventor： Masahiro Higashi ,  Yosuke Kishikawa ,  Tsugio Kitamura

IPC: C07C17/08 ,  C07C29/62 ,  C07C67/307

CPC classification number: C07C67/307 ,  C07C17/08 ,  C07C29/62

Abstract: The present disclosure addresses the problem of providing a novel method for producing a fluorinated iodinated organic compound.
The problem can be solved by a method for producing a fluorinated iodinated organic compound, comprising reacting a compound represented by formula (1):






wherein R1 and R2 are each independently a hydrogen atom, a halogen atom, or an organic group, or R1 and R2 optionally form a ring together with the two adjacent carbon atoms; and n is 1 or 2, with a fluorine source, an iodine source, and an oxidizing agent or radical generator to add fluorine and iodine to the double bond or triple bond.

公开(公告)号：US20230193350A1

公开(公告)日：2023-06-22

申请号：US17919735

申请日：2021-06-11

Applicant: Ohara Pharmaceutical Co., Ltd. ,  Saga University

Inventor： Yuki Kurahashi ,  Magoichi Sako ,  Hiroo Wakita ,  Shinya Kimura ,  Tatsuro Watanabe ,  Yuta Yamamoto

IPC: C12Q1/42 ,  A61K31/53 ,  A61K31/497 ,  A61P35/00

CPC classification number: C12Q1/42 ,  A61K31/53 ,  A61K31/497 ,  A61P35/00 ,  G01N2800/7028

Abstract: The present invention provides: a method for identifying a blood cancer patient who may benefit from a monotherapy using a drug comprising a DNA methyl transferase inhibitor and a combination therapy using the aforesaid drug together with another epigenetic controller; a pharmaceutical composition to be used in treating a patient who has been identified or selected by the method; and a kit for identifying such a patient. More particularly, the aforesaid method comprises a step for measuring the expression amount of DUSP5 in a sample obtained from a blood cancer patient. When the expression amount measured in this step is lower than a reference expression amount of DUSP5, then the patient is identified or selected as a blood cancer patient who may benefit from a treatment using the drug comprising a DNA methyl transferase inhibitor.

公开(公告)号：US20230097969A1

公开(公告)日：2023-03-30

申请号：US17796824

申请日：2020-10-01

Applicant: SAGA UNIVERSITY ,  NIPPON CONCRETE INDUSTRIES CO., LTD.

Inventor： Shin-ichi KAWAGUCHI ,  Takeshi SASAKI ,  Yasuyuki HAYAKAWA

IPC: C07F9/09 ,  C07F9/12

Abstract: A method for producing a phosphate diester or a phosphate triester is provided in which the phosphate diester or the phosphate triester can be produced from phosphoric acid and a hydroxy compound. Phosphoric acid and a phenol, which is used in excess with respect to the phosphoric acid, are subjected to dehydrating condensation with heating and refluxing. Water released during this dehydrating condensation is adsorbed onto a dehydrating material, which is an adsorbent derived from concrete sludge, disposed somewhere in the refluxing channel, thereby producing a phosphate diester or a phosphate triester.

公开(公告)号：US20220347197A1

公开(公告)日：2022-11-03

申请号：US17641083

申请日：2020-09-24

Applicant: Ohara Pharmaceutical Co., Ltd. ,  Saga University

Inventor： Magoichi Sako ,  Yuki Kurahashi ,  Shinya Kimura ,  Tatsuro Watanabe ,  Hiroshi Ureshino ,  Kazuharu Kamachi

IPC: A61K31/706

Abstract: [Problems] The object is to provide a compound as a therapeutic or prophylactic agent for TKI-resistant CML to replace the injection “Dacogen®” which has been clinically used as a therapeutic agent for high-risk myelodysplastic syndrome and acute myeloid leukemia. The said compound has remarkable stability against cytidine deaminase, a hydrolytic enzyme, and is absorbed in vivo even by oral administration, incorporated into the biosynthesis route of nucleic acid, and exhibits the effect of inhibiting DNA methyltransferase (DNMT).
[Solutions] A prophylactic or therapeutic agent for TKI-resistant CML, comprising a compound represented by formula (I) or a salt thereof, wherein R1 and R2 are each independently a hydrogen atom or a silyl group represented by formula (II): wherein R3, R4, and R5 are each independently an alkyl group which may have a substituent, an aryl group which may have a substituent, or an arylalkyl group which may have a substituent, with the provision that the case where both R1 and R2 are hydrogen atom is excluded.

公开(公告)号：US10814039B2

公开(公告)日：2020-10-27

申请号：US15405156

申请日：2017-01-12

Applicant: SAGA UNIVERSITY ,  KYOCERA Medical Corporation

Inventor： Masaaki Mawatari ,  Masatsugu Tsukamoto ,  Iwao Noda

IPC: A61L27/54 ,  A61L27/32

Abstract: Provided is a bioimplant which is capable to inhibit the biofilm formation over a long period of time after an operation. The bioimplant of the present invention comprises a base material of metal, ceramic, or plastic and a thermal spraying film of a calcium phosphate-based material formed at least partially thereon and the silver concentration in the thermal-spray film is 0.05 wt % to 3.00 wt %.

公开(公告)号：US20200289605A1

公开(公告)日：2020-09-17

申请号：US16889367

申请日：2020-06-01

Applicant: KOHJIN LIFE SCIENCES CO., LTD. ,  PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY ,  KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION ,  SAGA UNIVERSITY

Inventor： Takaomi KESSOKU ,  Atsushi NAKAJIMA ,  Yoshio SUMIDA ,  Yuichiro EGUCHI ,  Susumu SAITO ,  Yusuke SAUCHI

IPC: A61K38/06 ,  A61K38/00 ,  A61P1/16

Abstract: An object of the present invention is to provide a composition for preventing or improving fat deposition on the liver in spite of the alcohol intake history of a level that a liver disease is not caused. The inventors found that glutathione has an effect of preventing or improving fat deposition on the liver, which is not caused by alcohol, and completed the present invention. Among nonalcoholic fat diseases, the present invention is particularly effective in an early stage of the treatment or in a case where treatment for another disease is not performed.

公开(公告)号：US10460934B2

公开(公告)日：2019-10-29

申请号：US16106753

申请日：2018-08-21

Applicant: FLOSFIA INC. ,  NATIONAL INSTITUTE FOR MATERIALS SCIENCE ,  KYOTO UNIVERSITY ,  SAGA UNIVERSITY

Inventor： Yuichi Oshima ,  Shizuo Fujita ,  Kentaro Kaneko ,  Makoto Kasu ,  Katsuaki Kawara ,  Takashi Shinohe ,  Tokiyoshi Matsuda ,  Toshimi Hitora

IPC: H01L21/02 ,  H01L29/24 ,  H01L29/04 ,  H01L29/872

Abstract: According to an aspect of a present inventive subject matter, a crystalline film includes a crystalline metal oxide as a major component, the crystalline film includes a corundum structure, a surface area that is 9 μm2 or more, and a dislocation density that is less than 5×106 cm−2.